No announcement yet.

Potential of mesenchymal stem cells to treat traumatic brain injury

  • Filter
  • Time
  • Show
Clear All
new posts

    Potential of mesenchymal stem cells to treat traumatic brain injury

    Alison E. Willing, 1 Mahasweta Das, 2 , 3 Mark Howell, 2 , 3 Shyam S. Mohapatra, 3 , 4 and Subhra Mohapatra 2 , 3
    Author information Article notes Copyright and License information Disclaimer
    This article has been cited by other articles in PMC.
    Go to:Abstract

    Traumatic brain injury (TBI) causes death and disability in the United States and around the world. The traumatic insult causes the mechanical injury of the brain and primary cellular death. While a comprehensive pathological mechanism of TBI is still lacking, the focus of the TBI research is concentrated on understanding the pathophysiology and developing suitable therapeutic approaches. Given the complexities in pathophysiology involving interconnected immunologic, inflammatory, and neurological cascades occurring after TBI, the therapies directed to a single mechanism fail in the clinical trials. This has led to the development of the paradigm of a combination therapeutic approach against TBI. While there are no drugs available for the treatment of TBI, stem cell therapy has shown promising results in preclinical studies. But, the success of the therapy depends on the survival of the stem cells, which are limited by several factors including route of administration, health of the administered cells, and inflammatory microenvironment of the injured brain. Reducing the inflammation prior to cell administration may provide a better outcome of cell therapy following TBI. This review is focused on different therapeutic approaches of TBI and the present status of the clinical trials.
    “As the cast of villains in SCI is vast and collaborative, so too must be the chorus of hero's that rise to meet them” Ramer et al 2005